poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $120

Benzinga Newsdesk

HC Wainwright & Co. analyst Douglas Tsao maintains Disc Medicine (NASDAQ:IRON) with a Buy and raises the price target from $118 to $120.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IRON
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Na

    Disc Medicine to Participate in Upcoming Investor Conferences

    Disc Medicine (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on hematologic diseases, announced participation in four major investor conferences in September 2026. The company also reported completing a Type A FDA meeting on bitopertin with Phase 3 APOLLO study data expected in Q4 2026, which could serve as the basis for a Complete Response Letter (CRL) response.

    IRON
  3. Na

    Disc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

    Disc Medicine announced it will present clinical data from multiple programs at the SOHO 2026 Annual Meeting in Houston, including initial Phase 2 RESTORE-PV trial data for DISC-3405 in polycythemia vera patients and efficacy data from the RALLY-MF trial of DISC-0974 for myelofibrosis-associated anemia. The oral presentations are scheduled for September 9-12, 2026.

    IRON